Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.

Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.

BACKGROUND & AIMS:Since 2009/10, a 10- and a 13-valent pneumococcal conjugate vaccine (PCV) are available, but only the 10-valent vaccine is now being used for the children in the Netherlands. As the vaccines differ in number of serotypes, antigen concentration, and carrier proteins this study w...

Full description

Bibliographic Details
Main Authors:	Alienke J Wijmenga-Monsuur, Els van Westen, Mirjam J Knol, Riet M C Jongerius, Marta Zancolli, David Goldblatt, Pieter G M van Gageldonk, Irina Tcherniaeva, Guy A M Berbers, Nynke Y Rots
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4690595?pdf=render

Similar Items

Correction: Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
by: Alienke J Wijmenga-Monsuur, et al.
Published: (2016-01-01)

Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
by: Els van Westen, et al.
Published: (2018-12-01)

Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands.
by: Marloes Vissers, et al.
Published: (2018-01-01)

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
by: Trück, J, et al.
Published: (2016)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: Anna M.M. van Deursen, et al.
Published: (2012-11-01)

Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era.
by: Annemarijn C Prins-van Ginkel, et al.
Published: (2016-01-01)

Pneumococcal genetic variability in age-dependent bacterial carriage
by: Philip HC Kremer, et al.
Published: (2022-07-01)

Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups
by: Aapo Knuutila, et al.
Published: (2022-12-01)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
by: Paul Turner, et al.
Published: (2015-11-01)

Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.
by: Lindsay R Grant, et al.
Published: (2013-01-01)

Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.
by: Gerwin D Rodenburg, et al.
Published: (2012-01-01)

Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers.
by: Susanne P Stoof, et al.
Published: (2014-01-01)

Correction: Long-Term Effects of Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of and.
by: Judith Spijkerman, et al.
Published: (2012-01-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01)

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
by: Anita H. J. van den Biggelaar, et al.
Published: (2019-02-01)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
by: Irina Kislaya, et al.
Published: (2019-01-01)

A spitting image: molecular diagnostics applied to saliva enhance detection of Streptococcus pneumoniae and pneumococcal serotype carriage
by: Willem R. Miellet, et al.
Published: (2023-04-01)

Pneumococcal genetic variability in age-dependent bacterial carriage
by: Kremer, PHC, et al.
Published: (2022)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: A randomized clinical trial study
by: Mohammad Sadegh Rezai, et al.
Published: (2017-01-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Aishatu L. Adamu, et al.
Published: (2023-05-01)

Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis.
by: Judith Spijkerman, et al.
Published: (2012-01-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)

Lagging Immune Response to <i>Haemophilus influenzae</i> Serotype b (Hib) Conjugate Vaccine after the Primary Vaccination with Hib of Infants in The Netherlands
by: Leo Schouls, et al.
Published: (2020-06-01)

It Takes Two to Tango: Combining Conventional Culture With Molecular Diagnostics Enhances Accuracy of Streptococcus pneumoniae Detection and Pneumococcal Serogroup/Serotype Determination in Carriage
by: Willem R. Miellet, et al.
Published: (2022-04-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
by: Sabine Haggenburg, et al.
Published: (2023-07-01)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017-03-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Adamu, AL, et al.
Published: (2023)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-03-01)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-03-01)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-04-01)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023-09-01)

Nasopharyngeal carriage of pneumococcus in children in England up to 10 years after 13-valent pneumococcal conjugate vaccine introduction: persistence of serotypes 3 and 19A and emergence of 7C
by: Tiley, KS, et al.
Published: (2022)

Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
by: L A Shpagina, et al.
Published: (2018-11-01)

Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial
by: Kandasamy, R, et al.
Published: (2019)

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children
by: Ayieko, P, et al.
Published: (2013)

Decrease in pneumococcal co-colonization following vaccination with the seven-valent pneumococcal conjugate vaccine.
by: Carina Valente, et al.
Published: (2012-01-01)